Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 Apr. 19];7(6):s254. Available from: https://skin.dermsquared.com/skin/article/view/2441